ASTRAZENECA'S FASENRA RECEIVES APPROVAL
19 January 2018 07:00 GMT FASENRA RECEIVES APPROVAL IN JAPAN Approval based on Phase III WINDWARD programme that demonstrated significant reductions in asthma exacerbations, improvements in lung function and reductions in oral corticosteroid use from baseline, versus placebo Fasenra is the first approved respiratory biologic with an 8-week maintenance dosing schedule AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Japanese Ministry of Health, Labour and Welfare has approved Fasenra (benralizumab) as an add-on treatment